건선성 관절염 치료 시장 규모, 점유율, 성장 분석 : 약물 종류별, 투여 경로별, 치료 단계별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Psoriatic Arthritis Treatment Market size was valued at USD 12.52 Billion in 2024 and is poised to grow from USD 13.39 Billion in 2025 to USD 22.85 Billion by 2033, growing at a CAGR of 6.92% during the forecast period (2026-2033).

The psoriatic arthritis treatment market is experiencing significant growth driven by heightened awareness and the emergence of innovative therapies that have redefined treatment methodologies. Key market segments include biologics, enhanced copay assistance through insurance, increased access to generics, and non-drug therapies like occupational and physical therapy. The shift from traditional Disease Modifying Anti-Rheumatic Drugs (DMARDs) to advanced TNF-alpha inhibitors and IL-17 or IL-23 biopharmaceuticals has broadened treatment options and fostered improved patient compliance. Factors like refined diagnostic techniques and evolving reimbursement policies are pivotal in this growth, as they facilitate earlier access to targeted therapies. Additionally, advancements like musculoskeletal imaging and the introduction of oral JAK inhibitors have further diversified treatment strategies, enabling manufacturers to invest in patient support and real-world evidence initiatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Psoriatic Arthritis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Psoriatic Arthritis Treatment Market Segments Analysis

Global psoriatic arthritis treatment market is segmented by drug class, route, line of therapy, distribution and region. Based on drug class, the market is segmented into TNF inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, JAK inhibitors and PDE4 inhibitors. Based on route, the market is segmented into injectable and oral. Based on line of therapy, the market is segmented into first-line and second-line. Based on distribution, the market is segmented into hospital pharmacies, specialty pharmacies and online. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Psoriatic Arthritis Treatment Market

The global psoriatic arthritis treatment market is experiencing significant growth due to recent innovations in biologic therapies, which have expanded treatment options and enhanced clinical outcomes for patients. This progress has instilled greater confidence in healthcare professionals regarding the recommendation of targeted therapies. The effectiveness and tailored mechanisms of biologics have encouraged their widespread adoption among specialists, spurring ongoing research and development. Additionally, partnerships between biotechnology firms and healthcare providers have flourished, resulting in updated treatment guidelines and a heightened perception of the value offered by these innovative therapies. Such developments are driving market investment, introducing new agents, and expanding treatment access in both outpatient and hospital settings.

Restraints in the Global Psoriatic Arthritis Treatment Market

The elevated costs associated with advanced therapies are posing significant challenges for patient access while straining healthcare budgets. This situation often leads payers to adopt restrictive reimbursement policies and require prior authorizations, which can deter patients from adhering to treatment regimens. The financial burden may also discourage healthcare professionals from proposing these costly options, especially in under-resourced environments, and delay the inclusion of new treatment options in formularies. Such economic barriers restrict the potential market size, complicate access strategies for manufacturers, and ultimately hinder the rate of adoption despite the availability of clinically effective treatments, thereby constraining overall market growth.

Market Trends of the Global Psoriatic Arthritis Treatment Market

The Global Psoriatic Arthritis Treatment market is increasingly influenced by the shift towards precision medicine, focusing on molecularly targeted therapies that cater to individual patient profiles. This trend underscores the importance of biomarker-based patient stratification, facilitating the alignment of specific therapeutic agents with the unique mechanisms of each patient's disease. Collaboration among diagnostic and pharmaceutical stakeholders is enhancing the design of clinical trials and supporting systems that prioritize value-based reimbursement. Consequently, healthcare providers are leaning towards personalized treatment regimens, aiming to reduce trial-and-error prescribing while improving patient adherence, clinical outcomes, and minimizing adverse events through better predictability in therapeutic responses.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Psoriatic Arthritis Treatment Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• TNF Inhibitors
• IL-17 Inhibitors
• IL-12/23 Inhibitors
• JAK Inhibitors
• PDE4 Inhibitors

Global Psoriatic Arthritis Treatment Market Size by Route & CAGR (2026-2033)

• Market Overview
• Injectable
• Oral

Global Psoriatic Arthritis Treatment Market Size by Line of Therapy & CAGR (2026-2033)

• Market Overview
• First-Line
• Second-Line

Global Psoriatic Arthritis Treatment Market Size by Distribution & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Specialty Pharmacies
• Online

Global Psoriatic Arthritis Treatment Market Size by Region & CAGR (2026-2033)

• Market Overview
• North America
• Europe
• Asia-Pacific

Global Psoriatic Arthritis Treatment Market Size & CAGR (2026-2033)

• North America (Drug Class, Route, Line of Therapy, Distribution, Region)
  • US
  • Canada
• Europe (Drug Class, Route, Line of Therapy, Distribution, Region)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Route, Line of Therapy, Distribution, Region)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Route, Line of Therapy, Distribution, Region)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Route, Line of Therapy, Distribution, Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (Humira, Rinvoq)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (Tremfya, Simponi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (Enbrel, Xeljanz)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Cosentyx, Taltz co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly (Taltz)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB SA (Cimzia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (Orencia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (Enbrel co-marketed)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen (Otezla partnership)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene/BMS (Otezla)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galapagos NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences (Filgotinib)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moonlake Immunotherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acelyrin Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sonoma Biotherapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Affibody AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations